Back

Is it possible to start quadruple therapy in patients with a new diagnosis of HF and reduced ejection fraction? Real-life data from the TIDY-HF registry.

27 August 2022 (10:15 - 10:55)
Organised by:
Congress Presentation Part of: Chronic heart failure - Multidisciplinary interventions Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Alberto Esteban Fernandez

Severo Ochoa Hospital, Leganes (Spain)

5 More presentations in this session

Presentation thumbnail
Benefits of interventional telemonitoring in patients with chronic heart failure
Doctor A. Matta (Toulouse, FR)
Abstract Slides
Presentation thumbnail
A novel algorithm for rapid sequence optimization of guideline directed medical therapy for heart failure with reduced ejection fraction
Doctor A. Pandey (Ottawa, CA)
Abstract Slides
Presentation thumbnail
Device-based remote monitoring strategies for guided management of patients with heart failure: a systematic review and meta-analysis
Doctor A. Zito (Rome, IT)
Abstract Slides
Presentation thumbnail
Effect on mortality and hospitalization of real-world implementation of transitional care heart failure programmes in patients with heart failure: a population-based study in 77,554 patients.
Doctor J. Comin-Colet (Barcelona, ES)
Abstract Slides
Presentation thumbnail
A multidisciplinary program based on early care in a day hospital after heart failure hospitalizations. Reduction of 30-day readmissions in patients discharged from cardiology departments.
Doctor D. Vaqueriza Cubillo (Madrid, ES)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - Multidisciplinary interventions

The Event

Event poster

ESC Congress 2022

27 August 2022 10:15 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources